Resverlogix' Phase 1b/2a Program Commences for RVX-208

27-Aug-2008 - Canada

Resverlogix Corp. announced that the Phase 1b/2a program for the study of RVX-208 in subjects with normal lipids and those with low high-density lipoprotein (HDL) cholesterol has proceeded according to plan.

"We are very excited about moving forward into this important 28-day study with RVX-208. Our previous clinical study demonstrated that RVX-208 was safe, tolerable and had favourable pharmacokinetics," stated Dr.Allan Gordon, Senior Vice President Clinical Development of Resverlogix. "This trial will continue to examine safety and tolerance as well it is a proof of principle study for ApoA-I production and HDL functionality. Approximately half of the subjects will have low levels of HDL cholesterol, a condition associated with significant increased risk of cardiovascular disease," added Dr. Gordon.

"The ensuing Phase 1b/2a study comprises several novel facets to expedite the clinical process for RVX-208 and its eventual registration as a drug," statedDonald J. McCaffrey, President and CEO of Resverlogix. McCaffrey further confirmed, "Along with the required regulatory provisions that must be addressed such as safety, tolerance and pharmacokinetics, the study also will measure key reverse cholesterol transport markers which RVX-208 impacts. These are exclusive favourable features that make this drug unique among its competitors."

RVX-208, a novel small molecule therapeutic that facilitates endogenous ApoA-I production, is positioned to be one of the most promising emerging drugs in the treatment of atherosclerosis. To the Company's knowledge RVX-208 is the only novel small molecule that is specifically designed to increase ApoA-I production and thereby raise HDL levels thus enhancing HDL functionality to augment reverse cholesterol transport.

https://www.bionity.com/en/news/86169/resverlogix-phase-1b-2a-program-commences-for-rvx-208.html